These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 25312251)

  • 21. A new experimental rat model of erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: the testosterone-supplemented spontaneously hypertensive rat.
    Oudot A; Oger S; Behr-Roussel D; Caisey S; Bernabé J; Alexandre L; Giuliano F
    BJU Int; 2012 Nov; 110(9):1352-8. PubMed ID: 22448674
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The use of bioregulatory peptides in the treatment of men with benign prostatic hyperplasia and chronic prostatitis].
    Kuzmenko AV; Vinnik YY; Kuzmenko VV; Gyaurgiev TA
    Urologiia; 2021 Jun; (3):70-74. PubMed ID: 34251104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Testosterone and the Prostate: Artifacts and Truths.
    DeLay KJ; Kohler TS
    Urol Clin North Am; 2016 Aug; 43(3):405-12. PubMed ID: 27476133
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Benign prostatic hyperplasia (BPH) and prostatitis: prevalence of painful ejaculation in men with clinical BPH.
    Nickel JC; Elhilali M; Vallancien G;
    BJU Int; 2005 Mar; 95(4):571-4. PubMed ID: 15705082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study.
    Cindolo L; Pirozzi L; Fanizza C; Romero M; Tubaro A; Autorino R; De Nunzio C; Schips L
    Eur Urol; 2015 Sep; 68(3):418-25. PubMed ID: 25465970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New and Emerging Technologies in Treatment of Lower Urinary Tract Symptoms From Benign Prostatic Hyperplasia.
    Gupta NK; Gange SN; McVary KT
    Sex Med Rev; 2019 Jul; 7(3):491-498. PubMed ID: 29606553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.
    Sacco E; Bientinesi R; Marangi F; Totaro A; D'Addessi A; Racioppi M; Pinto F; Vittori M; Bassi P
    BJU Int; 2012 Dec; 110(11 Pt C):E837-44. PubMed ID: 22712582
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative Effectiveness of Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis.
    Dahm P; Brasure M; MacDonald R; Olson CM; Nelson VA; Fink HA; Rwabasonga B; Risk MC; Wilt TJ
    Eur Urol; 2017 Apr; 71(4):570-581. PubMed ID: 27717522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alpha-blockers for the Treatment of Benign Prostatic Hyperplasia.
    Lepor H
    Urol Clin North Am; 2016 Aug; 43(3):311-23. PubMed ID: 27476124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alpha-blockers with or without phosphodiesterase type 5 inhibitor for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis.
    Zhang J; Li X; Yang B; Wu C; Fan Y; Li H
    World J Urol; 2019 Jan; 37(1):143-153. PubMed ID: 29948047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation between benign prostatic hyperplasia and inflammation.
    Bostanci Y; Kazzazi A; Momtahen S; Laze J; Djavan B
    Curr Opin Urol; 2013 Jan; 23(1):5-10. PubMed ID: 23159991
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Extract of Serenoa repens in the treatment of benign prostatic hyperplasia and lower urinary tract symptoms].
    Amdii RE; Al' Shukri AS
    Urologiia; 2018 May; (2):114-120. PubMed ID: 29901305
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) combined responders to tadalafil after 12 weeks of treatment.
    Roehrborn CG; Egan KB; Miner MM; Ni X; Wong DG; Rosen RC
    BJU Int; 2016 Jul; 118(1):153-60. PubMed ID: 26765325
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [PDE5: A new therapeutic target for lower urinary tract symptoms/ benign prostatic hyperplasia combined with erectile dysfunction].
    Xu Z; Jia RP
    Zhonghua Nan Ke Xue; 2018 Apr; 24(4):355-359. PubMed ID: 30168958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging drugs to target lower urinary tract symptomatology (LUTS)/benign prostatic hyperplasia (BPH): focus on the prostate.
    Ückert S; Kedia GT; Tsikas D; Simon A; Bannowsky A; Kuczyk MA
    World J Urol; 2020 Jun; 38(6):1423-1435. PubMed ID: 31506747
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Link between circadian rhythm and benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS).
    Cavanaugh D; Urbanucci A; Mohamed NE; Tewari AK; Figueiro M; Kyprianou N
    Prostate; 2024 Apr; 84(5):417-425. PubMed ID: 38193363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PDE-5 Inhibitors for BPH-Associated LUTS.
    Brousil P; Shabbir M; Zacharakis E; Sahai A
    Curr Drug Targets; 2015; 16(11):1180-6. PubMed ID: 26470799
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of prostatic inflammation in the development and progression of benign and malignant diseases.
    Gandaglia G; Zaffuto E; Fossati N; Cucchiara V; Mirone V; Montorsi F; Briganti A
    Curr Opin Urol; 2017 Mar; 27(2):99-106. PubMed ID: 27906778
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer.
    Cicero AFG; Allkanjari O; Busetto GM; Cai T; Larganà G; Magri V; Perletti G; Robustelli Della Cuna FS; Russo GI; Stamatiou K; Trinchieri A; Vitalone A
    Arch Ital Urol Androl; 2019 Oct; 91(3):. PubMed ID: 31577095
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Observational database serenoa repens (DOSSER): overview, analysis and results. A multicentric SIUrO (Italian Society of Oncological Urology) project.
    Bertaccini A; Giampaoli M; Cividini R; Gattoni GL; Sanseverino R; Realfonso T; Napodano G; Fandella A; Guidoni E; Prezioso D; Galasso R; Cicalese C; Scattoni V; Armenio A; Conti G; Corinti M; Spasciani R; Liguori G; Lampropoulou N; Martorana G
    Arch Ital Urol Androl; 2012 Sep; 84(3):117-22. PubMed ID: 23210402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.